Preclinical Research
Leveraging Nonclinical Safety Evaluation Findings to Expedite Next-Generation Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) Development for Metabolic Disorders and Beyond
Intravenous Sampling and Administration Using InstechVascular Access Buttons in Rodents: Pathology Findings Related to Indwelling Vascular Catheter
Intra-Cerebroventricular (ICV) Route in Mice for Administration of Gene Therapy Products
Immunomodulatory Approaches in Preclinical Gene Therapy Studies
An Examination of the Effects of Body Temperature on QT Interval in Non-Naïve Telemetered Göttingen Minipigs®
GLP-1 RA: Overcoming Known Pharmacological Effects
4 Essential Topics to Cover in Your First CRO Meeting
Qualification of a Veterinary Glucometer for Use in Yucatan Miniature Swine
ISSUE NO. 42 — Managing The Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development
Current and future development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or simply GLP-1s, involves complexities not only in formulation but in all areas of early-phase drug development. Developing and refining preclinical models for early efficacy signals, developing and validating the bioanalytical assays necessary for quantitation, and designing the clinical studies that deliver the most robust data in this innovative therapeutic area are all key elements of a drug development program.
In Issue 42 of The Altascientist, we review the requirements for successful GLP-1 drug development, including:
- preclinical approaches
- early-phase clinical study design
- bioanalytical techniques
- manufacturing
Two case studies are also included.
Top Life Science Resources for Fall 2024
There’s a lot of life science content out there, so for your convenience, we’ve curated a selection of expert insights, tips, case studies, and scientific and regulatory information. Catch up on what you might have missed below!